Haystack MRD® receives New York State approval

Select providers now have access to Haystack MRD® via OncoEMR MPI capability 

We’re eager to share more news: Quest Diagnostics® has integrated Haystack MRD® ctDNA testing and Comprehensive Genomic Profiling into the OncoEMR® electronic health record system through their Molecular Profiling Integration (MPI) feature. All providers in the OncoEMR network will have access to these advanced tests in the second half of the year. 

This announcement from Quest Diagnostics underscores our goal to bring advanced testing directly and seamlessly into the clinical workflow, regardless of the EHR platform you use.

Read the press release here.

Subscribe for updates

No spam, notifications only about new products, updates.
News and events

Haystack MRD® receives New York State approval 

New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has officially approved Haystack MRD® for use in identifying residual or recurring disease in patients with solid tumor cancers.

Follow us on social media

Complete the form for instant access

Download the whitepaper

Patient access application mailing instructions

Haystack MRD
C/O Quest Diagnostics
2501 S State Hwy 121, Suite 1100
Lewisville, TX 75067

Para solicitar ayuda financiera, complete la solicitud y firme la autocertificación.

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Visit Johns Hopkins School of Medicine to learn more.
Visit Johns Hopkins School of Medicine to learn more.
Visit Johns Hopkins School of Medicine to learn more.